Arnold & Porter Advises on Launch of Life Sciences Investment Firm Banyan Bio
Arnold & Porter recently advised Banyan BioInnovations (“Banyan Bio”) in its launch as an investment firm. At the time of its launch, announced on May 5, 2026, Banyan Bio had secured more than $100…
Read the full articleYou might also wanna read
Biotech venture capital roundup: Osanni Bio leads with $190M Series B
Our latest roundup of venture capital financings in the biotech sector includes rounds for Osanni Bio, Bionyra, Serapha, Nura Bio, and Oblen
pharmaphorum.com·15d agoBiogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
This could be a key move for future growth.
BIO Launches National Campaign Highlighting Patient Stories Behind Biotechnology Breakthroughs
WASHINGTON, DC – Today, the Biotechnology Innovation Organization (BIO) announced the launch of The Fight of Our Lives, a new national cam
bio.org·1mo agoAlchemab Therapeutics extends Series A with £25m investment
Alchemab Therapeutics has extended its Series A financing with £25m from the British Business Bank, marking the Bank’s largest investment in
BioNTech’s investment provides a template for UK growth, say ABPI
The innovative biopharmaceutical company BioNTech has announced a major investment of up to £1bn over 10 years in the UK, potentially creati
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
Conditions : ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS Interventions : Drug: Foralumab Nasal; Drug: Plac
Comments
Sign in to join the conversation.
No comments yet. Be the first.